Down 10.4% in 4 Weeks, Here's Why Grifols (GRFS) Looks Ripe for a TurnaroundZacks Investment Research • 11/06/25
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technologyGlobeNewsWire • 06/10/25
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General MeetingBusiness Wire • 05/30/25
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?Zacks Investment Research • 05/28/25